Aprea Signals 2026 Inflection as Cancer Trials Advance and Cash Extends
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) told shareholders it is entering 2026 with advancing cancer programs, improving clinical signals, and a cash runway that management says extends into …
Aprea Signals 2026 Inflection as Cancer Trials Advance and Cash Extends Read More